Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Advanced Drainage Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.56 (market cap $29.60B), while Advanced Drainage Systems Inc trades at $140.33 (market cap $10.83B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WMS | |
|---|---|---|
Market Cap | $29.60B | $10.83B |
Sector | Health | Industrials |
52-Week High | $491.22 | $175.38 |
52-Week Low | $205.48 | $129.50 |
Enterprise Value | $27.56B | $12.44B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Advanced Drainage Systems (WMS) trades at $140.13, down 1.09% on the day, amid a bearish technical signal from moving averages. The company demonstrates strong profitability with a 14% net income margin and 24.9% ROE, supported by recent earnings beats. Revenue for fiscal 2025 was $2.90 billion, with cash flow from operations at $581.49 million. Analyst consensus is a Buy with a $185.86 price target, indicating significant upside potential from current levels.
The outlook for WMS is positive based on solid fundamentals and analyst optimism, though near-term technical weakness and competitive pressures pose risks. Investment appeal centers on earnings growth and market leadership in water management solutions, balanced by exposure to construction sector volatility and rising debt levels noted in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
